Skip to main content


UT-based Æglea Biotherapeutics raises $44 million in financing

Æglea Biotherapeutics—founded by one of the most prolific researchers in the fields of chemical and biomedical engineering George Georgiou—is developing treatments for inborn errors of metabolism and therapies that target tumor metabolism from engineered human enzymes.

» Read more

SXSW UT Village

» Going to SXSW? Check out the SXSW 2015 Innovation Showcase and Reception

» Read the coverage by Silicon Hills News

The Spring 2015 Tech News Brief is here

» Read the newsletter

Promising new diagnostic for highly fatal condition

America's greatest modern-day inventor visits UT Austin

Dr. Robert Langer joined UT Austin panelists Robert Metcalfe, Nicholas Peppas, and Dean Clay Johnston for a discussion on pursuing innovation. Widely known as the modern-day Thomas Edison, Langer has won over 220 major awards, holds more than 1,000 patents, and has launched various startups.

» Read more

First-of-its-kind institution at Dell Medical School takes on the nation's health care challenges

The Design Institute for Health is a collaboration between the new Dell Medical School and the College of Fine Arts at UT Austin to bring creative solutions to the health ecosystem.

» Read more

Pharmacyclics, founded on UT-based technology, sold to AbbVie for $21 billion

Established by UT Austin chemistry professor Jonathan Sessler, Pharmacyclics was acquired to boost the cancer drug pipeline at AbbVie with what is expected to be one of the world's top-selling cancer therapeutic drugs.

» Read more

Want OTC news delivered to your inbox? Subscribe now.